A股異動 | 奧園美谷(000615.SZ)逆勢漲近4% 擬6.97億元收購連天美55%股權
格隆匯3月19日丨奧園美谷(000615.SZ)逆勢漲近4%,報12.78元,總市值100億元。奧園美谷公佈,2021年3月18日,公司與廣州盛粧醫療美容投資有限公司於廣州共同簽署了《關於浙江連天美企業管理有限公司股權轉讓協議》,公司擬以現金方式收購盛粧醫美持有的浙江連天美企業管理有限公司的55%股權。此次交易評估機構出具的連天美100%股權評估值為13.51億元,經交易雙方協商確定的交易價格為6.97億元。此次股權轉讓完成後,公司將持有連天美55%的股權,連天美將成為公司的控股子公司。連天美主要從事醫療美容機構運營及管理業務,目前下設兩家醫療美容醫院。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.